Research Article Open Access

Chemistry and Pharmaceutical Perspectives of Licofelone Drug

Abstract

Inflammation has long been a symptom of many infectious diseases and is suggested to be closely associated to a wide range of non-infectious diseases. Inflammation's crucial role allows the development of new drugs to treat cancers, autoimmune disorders, and infectious diseases. Licofelone is a drug for osteoarthritis that is approved by the FDA. It blocks both the COX and 5-LOX pathways. Licofelone can relieve pain and reduce inflammation. It also protects nerve cells in the central nervous system, which may be related to how it controls the COX/5-LOX pathway, inflammatory cytokines, and immune responses. Better understanding of the chemistry and pharmacology of licofelone will be essential for demonstrating the potential efficacy of Licofelone in inflammatory conditions. The previously explored experimental findings for licofelone that were reviewed here lend support to the development of dual inhibitors of 5-LOX/COX as an alternative therapy to currently available NSAIDs. The findings strongly suggest that licofelone reduces LT and PG production via its inhibitory impact on 5-LOX, COX-1, and COX-2. So, it might be better than NSAIDs or selective COX-2 inhibitors in terms of clinically important benefits and effectiveness. However, further research needs to be done on a significant number of patients before we can be sure that this compound has an anti-inflammatory and analgesic impact in humans.

Iqra Rahat*, Yash Verma, Kaneez Fatima, Garima Garg, Umar Farooq

To read the full article Download Full Article | Visit Full Article